Shenzhen Shenxin Biotechnology Co., Ltd

This study is testing a new shingles vaccine that uses mRNA technology. It aims to see if the vaccine is safe and how well it triggers the body's immune defenses in healthy adults aged 50 to 79. The new vaccine will be compared directly to an already approved shingles vaccine.